- Home
- ADC vs AXSM Comparison
ADC vs AXSM Comparison
Compare ADC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADC | AXSM |
|---|---|---|
| Founded | 1971 | 2012 |
| Country | United States | United States |
| Employees | 90 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.0B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ADC | AXSM |
|---|---|---|
| Price | $79.74 | $160.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 17 |
| Target Price | $81.95 | ★ $209.18 |
| AVG Volume (30 Days) | ★ 1.2M | 468.7K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.94 | $58.34 |
| Revenue Next Year | $8.44 | $54.30 |
| P/E Ratio | $43.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $68.98 | $86.99 |
| 52 Week High | $82.08 | $191.50 |
Technical Indicators
Market Signals| Indicator | ADC | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 34.37 |
| Support Level | $70.94 | $148.14 |
| Resistance Level | $82.08 | $191.13 |
| Average True Range (ATR) | 1.18 | 5.42 |
| MACD | -0.19 | -1.09 |
| Stochastic Oscillator | 51.45 | 4.78 |
Price Performance
Historical ComparisonAbout ADC Agree Realty Corporation
Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.